HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup

Eli Lilly's weekly insulin jab Onswik set for NHS use if approved

Lilly's drug could cut the number of injections each patient needs by 85%.

By Pharmaceutical Technology · Aug 21, 2026 · via Pharmaceutical Technology
Eli Lilly's weekly insulin jab Onswik set for NHS use if approved

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Cytokinetics' cardiac myosin inhibitor, Myqorzo, is the first to demonstrate significant, clinically meaningfu…
Aug 28, 2026
The WeekFierceBiotech ↗
Roche's Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) desig…
Aug 28, 2026
STAT+: Cytokinetics details trial win for what could be its next approval
The WeekSTAT News ↗
It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second coul…
Aug 28, 2026